Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lu Zhang
Observed names:
L N Zhang,
Li Zhang
Institution:
First Hospital of Jilin University
Observed institutions:
Jilin University,
ShanghaiTech University,
Soochow University,
First Hospital of Jilin University,
State Key Laboratory of Respiratory Disease
ORCID:
0009-0000-7862-4321
Observed ORCID:
0009-0000-7862-4321
OpenAlex ID:
A5111245695
Comparative humoral profiles in mpox cases, survivors, and vaccinated individuals reveal correlates of protection against MPXV
2025
·
Yanqun Wang
, Lu Zhang
, et al.
·
Cell Reports Medicine
·
7
Case report and literature review: autonomous robotic system assisted palatal implantation at an anterior teeth site compromised by periapical cyst
2024
·
Xiuyu Liu
, Huixin Lv
, et al.
·
Frontiers in Medicine
·
7
PDF
Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2024
·
Shunli Dong
, Cong Ye
, et al.
·
Cancer Immunology Research
·
4
C‐X‐C Motif Chemokine Ligand 3 as a Potential Biomarker for Diagnosis and Prognosis of Diabetic Kidney Disease
2026
·
Sensen Su
, Xin Chen
, et al.
·
The FASEB Journal
·
3
Plasmodium yoelii surface-related antigen (PySRA) modulates the host pro-inflammatory responses via binding to CD68 on macrophage membrane
2024
·
Xin Feng
, Jia-Li Yu
, et al.
·
Infection and Immunity
·
3
[Research progress in the treatment of maxillary transverse deficiency with combined orthodontic-orthognathic approach].
2024
·
Y Wang
, X Z Ma
, et al.
·
PubMed
·
1
Supplementary Figure S2 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S1 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S4 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S9 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S7 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S5 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S8 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S3 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Table S6 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Table S5 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Table S3 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Table S4 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Table S1 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Table S2 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S6 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2026
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S1 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2025
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S9 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2025
·
Shunli Dong
, Cong Ye
, et al.
Table S2 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2025
·
Shunli Dong
, Cong Ye
, et al.
Supplementary Figure S4 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
2025
·
Shunli Dong
, Cong Ye
, et al.
PDF
Show more works
View as search
Works count:
39
Citation count:
25
H-index:
3
I10-index:
Year
Topic
Type